View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 15, 2021updated 11 Jul 2022 2:15pm

Lilly’s mirikizumab meets primary goal in Phase III ulcerative colitis trial

A greater decline from baseline in bowel urgency symptoms in subjects treated with mirikizumab were reported at one year.

Eli Lilly and Company has reported that its therapy, mirikizumab, met the primary and key secondary goals at one year in the Phase III LUCENT-2 clinical trial in moderately-to-severely active ulcerative colitis (UC) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A humanised IgG4 monoclonal antibody, mirikizumab attaches to the p19 subunit of interleukin 23.

The randomised, multicentre, placebo-controlled, double-blind maintenance trial enrolled subjects who were part of the Phase III LUCENT-1 trial.

The latest data build on the positive results from the LUCENT-1 induction study for 12-weeks.

Findings from the LUCENT-2 trial showed that a statistically greater proportion of subjects treated with mirikizumab met the primary goal of clinical remission at one year versus those in the placebo arm.

Clinical remission is attained when colon inflammation is managed or resolved, resulting in normalisation or near-normalisation of symptoms, including frequent and bloody faeces.

The trial met all the key secondary goals. Significantly greater proportions of subjects in the mirikizumab arm attained endoscopic remission, resolution or near-resolution of bowel urgency, corticosteroid-free remission, endoscopic histologic intestinal inflammation improvement and remission maintenance.

Furthermore, a significant decline from baseline in bowel urgency symptoms at one year versus placebo were noted.

The overall safety profile of mirikizumab in the trial was in line with previously reported data from UC trials and others within the anti-IL-23p19 antibody class.

Nasopharyngitis, arthralgia and exacerbation of ulcerative colitis were the most commonly observed adverse events linked to mirikizumab.

Lilly immunology development and US and global medical affairs vice-president Lotus Mallbris said: “Existing therapies aren’t fully meeting the needs of people with ulcerative colitis who still have unresolved symptoms that impact their health and quality of life.

“These positive long-term results provide evidence that mirikizumab has the potential to be an effective treatment option and become the first medicine of its kind for people with ulcerative colitis, including those who suffer from bowel urgency.”

The company intends to submit these data as part of a Biologics License Application (BLA) to the US Food and Drug Administration for mirikizumab in UC indication.

It will also seek approvals from various other regulatory authorities across the globe in the first half of next year.

This July, Lilly reported that mirikizumab stimulated gene expression changes in individuals with UC over a 12-week induction treatment in the Phase II trial.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena